Pacira BioSciences (PCRX) Stock Forecast, Price Target & Predictions
PCRX Stock Forecast
Pacira BioSciences stock forecast is as follows: an average price target of $35.00 (represents a 105.52% upside from PCRX’s last price of $17.03) and a rating consensus of 'Hold', based on 8 wall street analysts offering a 1-year stock forecast.
PCRX Price Target
The average price target for Pacira BioSciences (PCRX) is $35.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $63.00 to $8.00. This represents a potential 105.52% upside from PCRX's last price of $17.03.
PCRX Analyst Ratings
According to 8 Wall Street analysts, Pacira BioSciences's rating consensus is 'Hold'. The analyst rating breakdown for PCRX stock is 0 'Strong Buy' (0.00%), 3 'Buy' (37.50%), 5 'Hold' (62.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Pacira BioSciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 07, 2024 | David Amsellem | Piper Sandler | $12.00 | $17.36 | -30.90% | -29.54% |
| Sep 24, 2024 | Glen Santangelo | Jefferies | $18.00 | $14.77 | 21.87% | 5.70% |
| Aug 13, 2024 | Les Sulewski | Truist Financial | $8.00 | $12.29 | -34.91% | -53.02% |
| Jul 02, 2024 | Oren Livnat | H.C. Wainwright | $57.00 | $21.91 | 160.16% | 234.70% |
| Jun 13, 2024 | Glen Santangelo | Jefferies | $36.00 | $28.50 | 26.32% | 111.39% |
| May 21, 2024 | David Amsellem | Piper Sandler | $42.00 | $30.68 | 36.88% | 146.62% |
| Jan 06, 2023 | - | BMO Capital | $52.00 | $38.50 | 35.06% | 205.34% |
| Jan 06, 2023 | - | Needham | $63.00 | $38.50 | 63.64% | 269.94% |
The latest Pacira BioSciences stock forecast, released on Nov 07, 2024 by David Amsellem from Piper Sandler, set a price target of $12.00, which represents a -30.90% decrease from the stock price at the time of the forecast ($17.36), and a -29.54% decrease from PCRX last price ($17.03).
Pacira BioSciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 6 |
| Avg Price Target | $12.00 | $15.00 | $28.83 |
| Last Closing Price | $17.03 | $17.03 | $17.03 |
| Upside/Downside | -29.54% | -11.92% | 69.29% |
In the current month, the average price target of Pacira BioSciences stock is $12.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -29.54% decrease as opposed to Pacira BioSciences's last price of $17.03. This month's average price target is down -20.00% compared to last quarter, and down -58.38% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 07, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 24, 2024 | Truist Financial | Sector Perform | Sector Perform | Hold |
| Sep 24, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 24, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 12, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Aug 12, 2024 | RBC Capital | Underperform | Sector Perform | Downgrade |
| Aug 12, 2024 | Raymond James | Underperform | Market Perform | Downgrade |
| Aug 12, 2024 | Piper Sandler | Buy | Neutral | Downgrade |
| Jul 25, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jul 25, 2024 | Needham | Underperform | Underperform | Hold |
Pacira BioSciences's last stock rating was published by Piper Sandler on Nov 07, 2024. The company gave PCRX a "Neutral" rating, the same as its previous rate.
Pacira BioSciences Financial Forecast
Pacira BioSciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $181.24M | $163.93M | $169.47M | $160.34M | $171.96M | $167.47M | $169.41M | $157.99M | $159.19M | $127.72M | $135.59M | $119.03M | $130.97M | $117.48M | $75.50M | $105.68M | $122.42M | $104.69M | $102.60M | $91.31M | $74.61M | $69.28M |
| Avg Forecast | $158.28M | $152.05M | $161.49M | $161.92M | $180.39M | $169.55M | $173.70M | $165.32M | $180.62M | $172.95M | $174.85M | $159.19M | $171.94M | $168.33M | $170.64M | $159.72M | $156.29M | $129.42M | $132.48M | $119.31M | $131.66M | $116.13M | $72.08M | $101.68M | $121.22M | $105.02M | $100.43M | $92.36M | $74.61M | $14.59M |
| High Forecast | $169.66M | $162.98M | $173.10M | $179.11M | $187.87M | $169.91M | $173.70M | $165.32M | $181.23M | $173.18M | $187.42M | $170.63M | $184.30M | $168.33M | $170.64M | $159.72M | $156.29M | $129.42M | $132.48M | $119.31M | $131.66M | $116.13M | $72.08M | $101.68M | $121.22M | $105.02M | $100.43M | $92.36M | $89.53M | $17.50M |
| Low Forecast | $142.37M | $136.77M | $145.26M | $135.97M | $169.20M | $169.19M | $173.70M | $165.32M | $179.71M | $172.71M | $157.28M | $143.19M | $154.66M | $168.33M | $170.64M | $159.72M | $156.29M | $129.42M | $132.48M | $119.31M | $131.66M | $116.13M | $72.08M | $101.68M | $121.22M | $105.02M | $100.43M | $92.36M | $59.69M | $11.67M |
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Surprise % | - | - | - | - | - | - | - | - | 1.00% | 0.95% | 0.97% | 1.01% | 1.00% | 0.99% | 0.99% | 0.99% | 1.02% | 0.99% | 1.02% | 1.00% | 0.99% | 1.01% | 1.05% | 1.04% | 1.01% | 1.00% | 1.02% | 0.99% | 1.00% | 4.75% |
Pacira BioSciences's average Quarter revenue forecast for Mar 24 based on 4 analysts is $165.32M, with a low forecast of $165.32M, and a high forecast of $165.32M. PCRX's average Quarter revenue forecast represents a -8.79% decrease compared to the company's last Quarter revenue of $181.24M (Dec 23).
Pacira BioSciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EBITDA | - | - | - | - | - | - | - | - | $33.17M | $17.72M | $39.88M | $26.47M | $31.43M | $31.71M | $32.77M | $40.73M | $16.52M | $36.63M | $36.91M | $23.89M | $24.17M | $17.69M | $2.69M | $18.96M | $7.11M | $5.30M | $11.86M | $6.48M | $-3.13M | $-14.34M |
| Avg Forecast | $30.97M | $29.75M | $31.60M | $31.68M | $35.29M | $33.17M | $33.99M | $54.12M | $35.34M | $33.84M | $34.21M | $49.20M | $16.76M | $32.10M | $32.54M | $44.73M | $29.81M | $24.68M | $25.26M | $28.00M | $25.11M | $22.15M | $13.75M | $16.03M | $23.12M | $20.03M | $19.15M | $7.47M | $-3.13M | $-35.50M |
| High Forecast | $33.19M | $31.89M | $33.87M | $35.04M | $36.76M | $33.24M | $33.99M | $64.94M | $35.46M | $33.88M | $36.67M | $59.04M | $20.11M | $32.10M | $32.54M | $53.67M | $29.81M | $24.68M | $25.26M | $33.60M | $25.11M | $22.15M | $13.75M | $19.24M | $23.12M | $20.03M | $19.15M | $8.97M | $-2.50M | $-28.40M |
| Low Forecast | $27.86M | $26.76M | $28.42M | $26.60M | $33.10M | $33.10M | $33.99M | $43.29M | $35.16M | $33.79M | $30.77M | $39.36M | $13.40M | $32.10M | $32.54M | $35.78M | $29.81M | $24.68M | $25.26M | $22.40M | $25.11M | $22.15M | $13.75M | $12.83M | $23.12M | $20.03M | $19.15M | $5.98M | $-3.75M | $-42.60M |
| Surprise % | - | - | - | - | - | - | - | - | 0.94% | 0.52% | 1.17% | 0.54% | 1.88% | 0.99% | 1.01% | 0.91% | 0.55% | 1.48% | 1.46% | 0.85% | 0.96% | 0.80% | 0.20% | 1.18% | 0.31% | 0.26% | 0.62% | 0.87% | 1.00% | 0.40% |
4 analysts predict PCRX's average Quarter EBITDA for Mar 24 to be $54.12M, with a high of $64.94M and a low of $43.29M. This is 63.16% upper than Pacira BioSciences's previous annual EBITDA (Dec 23) of $33.17M.
Pacira BioSciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| Net Income | - | - | - | - | - | - | - | - | $24.87M | $22.34M | $25.76M | $-19.54M | $-10.10M | $-693.00K | $19.88M | $6.83M | $-5.13M | $17.66M | $19.08M | $10.37M | $14.52M | $130.12M | $-7.27M | $8.16M | $-4.89M | $-6.09M | $2.73M | $-2.77M | $-10.68M | $-19.87M |
| Avg Forecast | $33.46M | $31.16M | $32.83M | $29.60M | $36.16M | $32.50M | $32.24M | $10.15M | $40.75M | $36.01M | $35.00M | $9.23M | $-5.20M | $38.74M | $43.07M | $8.39M | $45.64M | $32.85M | $35.67M | $12.15M | $41.69M | $32.92M | $4.69M | $6.90M | $22.18M | $16.46M | $17.49M | $-3.20M | $-10.68M | $-49.17M |
| High Forecast | $36.59M | $34.07M | $35.90M | $31.08M | $40.13M | $32.97M | $32.25M | $12.18M | $44.87M | $36.12M | $38.27M | $11.08M | $-4.16M | $38.74M | $43.07M | $10.07M | $45.64M | $32.85M | $35.67M | $14.58M | $41.69M | $32.92M | $4.69M | $8.28M | $22.18M | $16.46M | $17.49M | $-2.56M | $-8.54M | $-39.33M |
| Low Forecast | $29.09M | $27.08M | $28.54M | $27.01M | $33.51M | $32.03M | $32.24M | $8.12M | $37.54M | $35.91M | $30.43M | $7.38M | $-6.24M | $38.74M | $43.07M | $6.71M | $45.64M | $32.85M | $35.67M | $9.72M | $41.69M | $32.92M | $4.69M | $5.52M | $22.18M | $16.46M | $17.49M | $-3.84M | $-12.82M | $-59.00M |
| Surprise % | - | - | - | - | - | - | - | - | 0.61% | 0.62% | 0.74% | -2.12% | 1.94% | -0.02% | 0.46% | 0.81% | -0.11% | 0.54% | 0.53% | 0.85% | 0.35% | 3.95% | -1.55% | 1.18% | -0.22% | -0.37% | 0.16% | 0.87% | 1.00% | 0.40% |
Pacira BioSciences's average Quarter net income forecast for Mar 24 is $10.15M, with a range of $8.12M to $12.18M. PCRX's average Quarter net income forecast represents a -59.18% decrease compared to the company's last Quarter net income of $24.87M (Dec 23).
Pacira BioSciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| SG&A | - | - | - | - | - | - | - | - | $65.80M | $67.95M | $64.85M | $70.84M | $63.97M | $61.28M | $65.00M | $64.26M | $51.20M | $48.81M | $50.81M | $48.52M | $52.83M | $52.56M | $43.34M | $44.78M | $54.22M | $50.13M | $49.13M | $48.52M | $44.19M | $42.12M |
| Avg Forecast | $66.03M | $63.43M | $67.37M | $67.54M | $75.25M | $70.73M | $72.46M | $95.55M | $75.34M | $72.14M | $72.94M | $86.87M | $51.94M | $70.22M | $71.18M | $78.97M | $65.20M | $53.99M | $55.26M | $56.86M | $54.92M | $48.44M | $30.07M | $37.87M | $50.57M | $43.81M | $41.89M | $55.98M | $44.19M | $6.08M |
| High Forecast | $70.77M | $67.99M | $72.21M | $74.71M | $78.37M | $70.87M | $72.46M | $114.66M | $75.60M | $72.24M | $78.18M | $104.24M | $62.33M | $70.22M | $71.18M | $94.76M | $65.20M | $53.99M | $55.26M | $68.23M | $54.92M | $48.44M | $30.07M | $45.44M | $50.57M | $43.81M | $41.89M | $67.18M | $53.03M | $7.30M |
| Low Forecast | $59.39M | $57.05M | $60.59M | $56.72M | $70.58M | $70.58M | $72.46M | $76.44M | $74.96M | $72.05M | $65.61M | $69.49M | $41.55M | $70.22M | $71.18M | $63.18M | $65.20M | $53.99M | $55.26M | $45.49M | $54.92M | $48.44M | $30.07M | $30.29M | $50.57M | $43.81M | $41.89M | $44.79M | $35.35M | $4.87M |
| Surprise % | - | - | - | - | - | - | - | - | 0.87% | 0.94% | 0.89% | 0.82% | 1.23% | 0.87% | 0.91% | 0.81% | 0.79% | 0.90% | 0.92% | 0.85% | 0.96% | 1.09% | 1.44% | 1.18% | 1.07% | 1.14% | 1.17% | 0.87% | 1.00% | 6.92% |
Pacira BioSciences's average Quarter SG&A projection for Mar 24 is $95.55M, based on 4 Wall Street analysts, with a range of $76.44M to $114.66M. The forecast indicates a 45.22% rise compared to PCRX last annual SG&A of $65.80M (Dec 23).
Pacira BioSciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 3 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 13 | 8 | 8 | 9 | 12 | 7 | 7 | 8 | 16 | 12 |
| EPS | - | - | - | - | - | - | - | - | $0.48 | $0.48 | $0.56 | $-0.43 | $-0.22 | $-0.02 | $0.44 | $0.15 | $-0.12 | $0.40 | $0.43 | $0.24 | $0.33 | $3.03 | $-0.17 | $0.19 | $-0.12 | $-0.15 | $0.07 | $-0.07 | $-0.26 | $-0.52 |
| Avg Forecast | $0.73 | $0.68 | $0.71 | $0.64 | $0.78 | $0.70 | $0.70 | $0.62 | $0.88 | $0.78 | $0.76 | $0.62 | $0.83 | $0.77 | $0.85 | $0.83 | $0.90 | $0.65 | $0.71 | $0.64 | $0.82 | $0.65 | $0.09 | $0.30 | $0.44 | $0.33 | $0.35 | $0.26 | $0.02 | $-0.10 |
| High Forecast | $0.79 | $0.74 | $0.78 | $0.67 | $0.87 | $0.71 | $0.70 | $0.62 | $0.97 | $0.78 | $0.83 | $0.67 | $0.91 | $0.77 | $0.85 | $0.83 | $0.90 | $0.65 | $0.71 | $0.64 | $0.82 | $0.65 | $0.09 | $0.30 | $0.44 | $0.33 | $0.35 | $0.26 | $0.02 | $-0.08 |
| Low Forecast | $0.63 | $0.59 | $0.62 | $0.59 | $0.73 | $0.69 | $0.70 | $0.62 | $0.81 | $0.78 | $0.66 | $0.54 | $0.72 | $0.77 | $0.85 | $0.83 | $0.90 | $0.65 | $0.71 | $0.64 | $0.82 | $0.65 | $0.09 | $0.30 | $0.44 | $0.33 | $0.35 | $0.26 | $0.02 | $-0.12 |
| Surprise % | - | - | - | - | - | - | - | - | 0.54% | 0.61% | 0.74% | -0.70% | -0.27% | -0.02% | 0.52% | 0.18% | -0.13% | 0.62% | 0.61% | 0.38% | 0.40% | 4.65% | -1.83% | 0.64% | -0.27% | -0.46% | 0.20% | -0.27% | -13.00% | 5.20% |
According to 4 Wall Street analysts, Pacira BioSciences's projected average Quarter EPS for Mar 24 is $0.62, with a low estimate of $0.62 and a high estimate of $0.62. This represents a 29.19% increase compared to PCRX previous annual EPS of $0.48 (Dec 23).
Pacira BioSciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PCRX | Pacira BioSciences | $17.03 | $35.00 | 105.52% | Hold |
| ANIP | ANI Pharmaceuticals | $55.10 | $79.00 | 43.38% | Buy |
| COLL | Collegium Pharmaceutical | $30.00 | $40.50 | 35.00% | Buy |
| ALKS | Alkermes | $27.91 | $36.38 | 30.35% | Hold |
| ITCI | Intra-Cellular Therapies | $85.64 | $94.50 | 10.35% | Buy |
| PBH | Prestige Consumer Healthcare | $82.67 | $89.50 | 8.26% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| HCM | HUTCHMED (China) | $17.96 | $17.50 | -2.56% | Buy |
| PAHC | Phibro Animal Health | $23.39 | $18.67 | -20.18% | Buy |